Emergence of novel *Leptospira* serovars: a need for adjusting vaccination policies for dogs?

Z. J. ARENT[1]*, S. ANDREWS[2], K. ADAMAMA-MORAITOU[3], C. GILMORE[1],
D. PARDALI[3] AND W. A. ELLIS[1]

[1] *OIE Leptospirosis Reference Laboratory, Agri-Food and Biosciences Institute, Veterinary Sciences Division, Belfast, Northern Ireland, UK*
[2] *Pfizer Limited, Sandwich, Kent, UK*
[3] *Companion Animal Clinic, Faculty of Veterinary Medicine, Aristotle University of Thessaloniki, Greece*

SUMMARY

A total of 855 sera from dogs in Greece were tested for antibodies to strains belonging to the Pomona, Grippotyphosa and Australis serogroups of *Leptospira* to assess exposure levels to these serogroups, possible associations with clinical disease and to evaluate whether these findings support the inclusion of additional serovars in dog vaccines. Antibodies were detected in 110 (12·9%) dogs. The highest seroprevalence (4·9%) was to the proposed novel serovar Altodouro belonging to the Pomona serogroup. This serovar also showed a statistically significant association with clinical disease. Serovar Bratislava antibodies were found in 3·4% of sera. Consideration should be given to the inclusion of serovars belonging to the Pomona serogroup and serovar Bratislava in future dog vaccines for the Greek market.

Key words: Dog, *Leptospira*, leptospirosis, vaccine, MAT.

INTRODUCTION

Leptospirosis is presumed to be the most widespread zoonosis in the world. It can be transmitted, in both man and animals, by direct or indirect contact with infected materials. Infected animals excrete leptospires in their urine, which constitute the primary route for further transmission of the infection through contact with contaminated water and soil or urine itself [1]. Dogs are significant reservoir for human infection and may be an important source of outbreaks [2].

Canine leptospirosis occurs worldwide and was recognized as a disease of dogs in 1899 before it was recognized in any other animal species, including humans [3, 4]. Traditionally, canine leptospirosis has mainly been associated with serovars Canicola and Icterohaemorrhagiae, which are from two different serogroups within *Leptospira interrogans* species. Leptospires are known to be highly pathogenic in dogs and four syndromes have been identified in infected dogs: icteric, haemorrhagic, uraemic and reproductive [1]. None of them are exclusively associated with one serovar. Detection of antibodies against the surface antigens of the various leptospiral serovars by the microscopic agglutination test (MAT) is the most common test for leptospirosis [1].

Recent publications from around the world, including Europe, have highlighted the re-emergence of

* Author for correspondence: Dr Z. J. Arent, OIE Leptospirosis Reference Laboratory, Agri-Food and Biosciences Institute, Veterinary Sciences Division, Stoney Road, Stormont, Belfast BT4 3SD, Northern Ireland, UK.
(Email: zbigniew.arent@afbini.gov.uk)

canine leptospirosis and its zoonotic potential. A recent study in Ireland indicated that 7% of domestic dogs were shedding leptospires in their urine [5] and in Germany an increase in the number of human cases has in part been attributed to resurgence of canine leptospirosis [6]. Leptospirosis has also appeared as a sporadic human health problem in Greece and severe fatal syndrome occurs every year [7–9].

Vaccines for the protection of dogs against *L. interrogans* infection have been available in Europe for about 50 years [10]. Traditionally these included serovars Canicola and Icterohaemorrhagiae. Since vaccine immunity is primarily serovar-specific, infection with serovars other than Canicola and Icterohaemorrhagiae infection by other serovars cannot be controlled by the currently available vaccines. Reports from some parts of Europe indicate an altered epidemiological situation and there have been calls for an expansion of the number of *Leptospira* serovars included in vaccines to reflect the most prevalent serovars currently found in dogs [11, 12]. Changes in the epidemiology of canine leptospirosis in North America have resulted in the inclusion of serovars Grippotyphosa and Pomona in bacterins available there. In Europe, vaccine manufacturers are actively reviewing the strains of *Leptospira* that should be included in dog vaccines [13] and whether there is common ground between European and North American requirements. A review of the evidence for such changes found a lack of recent published information on canine leptospirosis in many parts of Europe [14]. Vaccine manufacturers prefer to seek licences on a European Union (EU)-wide basis rather on a country-by-country basis. Serovars appropriate for inclusion in dog vaccines for countries where there is recent prevalence data, may not be appropriate for all member states, Greece was selected for the present study because it is one of the EU member states for which there is limited information [15]. The purpose of this study was to investigate the seroprevalence of potential vaccine candidate strains in dogs in northern Greece in order to evaluate whether there is supporting evidence for the inclusion of serovars Grippotyphosa, Pomona and Bratislava in dog vaccines. In addition, serovar Bratislava has been included in this survey as it was identified as another likely European vaccine candidate [14]. European strains of the Pomona serogroup (Mozdok and Altoduoro) were included for the first time as they are more appropriate to European studies than serovar Pomona [14, 16].

MATERIALS AND METHODS

Serum samples from 855 dogs (469 females, 386 males) were collected by the Companion Animal Clinic, Faculty of Veterinary Medicine, Aristotle University of Thessaloniki between 2006 and 2010. Most of the sera (697, 81·5%) came from dogs which had been vaccinated against serovars Icterohaemorrhagiae and Canicola. The sera were stored frozen at the clinic prior to shipping to the *Leptospira* laboratory in Belfast accompanied by the relevant clinical veterinary information.

All samples were tested for leptospiral antibodies by MAT [17] using live antigens of *L. interrogans* serovar Bratislava, *L. kirschneri* serovar Grippotyphosa and three antigens representing the Pomona serogroup of leptospires – *L. interrogans* serovar Pomona, *L. kirschneri* serovar Mozdok, and the putative new serovar Altodouro (strain Rim 139) [16].

Each antigen was grown in 10 ml volume of EMJH medium, incubated at 28 °C. After 6–10 days' growth (depending on the antigen) antigens were adjusted to $1–2 \times 10^8$ cells/ml by cell count using a counting chamber.

The sera were initially scanned for antibodies to the five antigens at a final dilution of 1:30 and 1:300 being incubated for 2 h at 28 °C. Where there was evidence of agglutination the relevant sera were end-point tested using dilution patterns proposed by Ellis & Michna [18] from 1:10 to 1:30000.

The serological titre for any serovar was considered to be the highest dilution where there was sufficient antibody present to agglutinate $\geqslant 50\%$ of the antigen with the exception of the 1/10 dilution where there was required to be 75% agglutination of the antigen.

Dogs were deemed to have been exposed to infection when titres of 1:10 or greater were detected and seroprevalence in this study was defined as the proportion of submitted samples with positive MAT results. For any positive sample, the infecting serovar was assumed to be that which demonstrated the highest titre and the lower titres were considered to be cross-reactions.

All statistical analyses were performed on data from the seropositive dogs and the serovars to which they were likely exposed. Risk factors for the presence of *Leptospira* antibodies were assessed by nominal logistic regression analysis. The strength of association between seropositivity and other variables, were estimated by the calculation of odds ratio (OR), and OR with a lower 95% confidence interval (CI) >1

Table 1. *Positive results of the microscopic agglutination test by presumed serovar and serogroup of 855 dogs*

Presumed serovar	Serogroup	No. of cases	%
Altodouro	Pomona	42	4·9
Bratislava	Australis	29	3·4
Mozdok	Pomona	16	1·9
Grippotyphosa	Grippotyphosa	10	1·2
Pomona	Pomona	2	0·2
Cross-reactions*			
Altodouro/Bratislava		4	0·5
Altodouro/Mozdok		2	0·2
Altodouro/Mozdok/Grippotyphosa		1	0·1
Bratislava/Grippotyphosa		1	0·1
Bratislava/Mozdok		2	0·2
Grippotyphosa/Pomona		1	0·1
Total		110	12·9

* Cross-reactions at equal titres.

was taken to indicate a significant association [19]. There were several variables analysed, such as age, origin (rural/urban) and sex.

RESULTS

The results of serological tests of 855 dogs are reported in Tables 1 and 2. A total of 110 (12·9%) dogs had antibody titres of 1:10 or greater to at least one of five serovars used in the study. The majority (91·8%) of positive samples demonstrated low titres ($\leqslant$1:100). The highest titres $\geqslant$1:1000 were determined for two (1·8%) samples with serovar Altodouro.

Titres to the Pomona serogroup were the most common with antibodies to serovar Altodouro being present in 4·9% of sera with titres ranging from 1:10 to 1:3000. Antibodies to the other Pomona serogroup strains were much less common with seroprevalences for Mozdok (titre range 1:10 to 1:100) and Pomona of 1·9% and 0·2%, respectively. Only 1:10 titres were detected to serovar Pomona. Serovar Bratislava was the second most prevalent serovar (3·4%) with titres ranging from 1:10 to 1:300. The serological prevalence for Grippotyphosa was 1·2%, with titres from 1:10 to 1:100. Multiple reactions, at equal titres, were observed in 1·3% of the sera tested.

Most (88·2%) positive dogs were reported to be clinically healthy. No significant association was found between a diagnosis of leptospirosis and the presence of antibodies to serovars Bratislava, Mozdok, Pomona and Grippotyphosa. A significant

association was observed in relation to serovar Altodouro. Of positive dogs, only 12·2% of vaccinated dogs and 15·8% of unvaccinated dogs had exposure to at least one serovar (OR 0·739, 95% CI 0·456–1·199).

Seroprevalences for all positive dogs were similar in those living in rural areas (13·1%) compared to those living in urban regions (12·2%) with the exception of serovar Altodouro where a greater, but not significant, difference was observed – 5·4% for rural and 3·5% for urban dogs (OR 1·596, 95% CI 0·728–3·502).

When seroprevalences for all five serovars were considered together with respect to age, a higher rate was observed in dogs aged between 1 and 5·9 years. At this age the dogs appeared to be more likely to have antibodies to serovar Altodouro (6·8%; OR 2·015, 95% CI 1·071–3·790). Older dogs aged >10 years were more likely to have antibodies to Grippotyphosa (3·0%; OR 3·267, 95% CI 0·831–12·841), the age category 6–9·9 years was significant for antibodies to serovar Mozdok (3·2%; OR 2·888, 95% CI 1·040–8·024). No statistical difference was detected regarding the other serovars (Table 3).

There was a higher prevalence of antibodies to all serovars in females (14·1%) than in males (11·4%) (OR 1·090, 95% CI 0·689–1·723); however, sex was not significantly associated with exposure of leptospirosis. The prevalence of antibodies to serovar Altodouro was higher in females (6·2%) than males (3·4%), but no significant difference was found between them (OR 1·596, 95% CI 0·728–3·502).

DISCUSSION

There are two points which must be considered when assessing the value of including new serovars in a dog vaccine. First, whether there is evidence of the serovar causing clinical disease in dogs and second, whether dogs are being infected by that serovar and therefore likely to be a risk factor for human leptospirosis or leptospirosis in other domestic animals.

This study has shown that dogs in northern Greece are being exposed to infection by strains of the Pomona serogroup, serovar Bratislava and occasionally serovar Grippotyphosa. Whether dogs are persistently infected with any of these remains to be determined as this can only be assessed by renal culture which was not part of this study.

The very low seroprevalence to serovar Pomona is consistent with the very low prevalence to this serovar

Table 2. *Distribution of antibody titres to five* Leptospira *serovars in 110 dogs*

	Number of serum samples						
Serovar	1:10	1:30	1:100	1:300	1:1000	1:3000	Total
Altodouro	15	12	9	4	1	1	42
Bratislava	7	16	4	2			29
Mozdok	10	5	1				16
Grippotyphosa	6	3	1				10
Pomona	2						2
Cross-reactions*							
Altodouro/Bratislava		1	2	1			4
Altodouro/Mozdok		2					2
Altodouro/Mozdok/Grippotyphosa	1						1
Bratislava/Grippotyphosa		1					1
Bratislava/Mozdok	1		1				2
Grippotyphosa/Pomona	1						1
Total	43	40	18	7	1	1	110

* Cross-reactions at equal titres.

Table 3. Leptospira *seroprevalence by age, sex and origin*

		Seroreactivity, % (*n*)					
Risk factor	Total	Reactive samples	Bratislava	Pomona	Mozdok	Grippo-typhosa	Altodouro
Age (yr)							
<1	69	11·6 (8)	2·9 (2)	0·0 (0)	2·9 (2)	0·0 (0)	5·8 (4)
1–5·9	368	14·4 (53)	3·3 (12)	0·5 (2)	0·8 (3)	0·8 (3)	6·8 (25)*
6–9·9	317	11·8 (38)	3·8 (12)	0·0 (0)	3·2 (10)*	1·3 (4)	3·2 (10)
⩾10	101	10·9 (11)	3·0 (3)	0·0 (0)	1·0 (1)	3·0 (3)*	3·0 (3)
Sex							
Male	386	11·4 (44)	3·1 (12)	0·0 (0)	2·1 (8)	1·3 (5)	3·4 (13)
Famale	469	14·1 (66)	3·6 (17)	0·4 (2)	1·7 (8)	1·1 (5)	6·2 (29)
Origin							
Urban	230	12·2 (28)	3·0 (7)	0·4 (1)	2·2 (5)	1·7 (4)	3·5 (8)
Rural	625	13·1 (82)	3·5 (22)	0·2 (1)	1·8 (11)	1·0 (6)	5·4 (34)

* Results statistically significant.

found across most of Europe, with the exception of Romania [20]. This low seroprevalence in Europe led Ellis [14] to conclude that there was no case for the inclusion of serovar Pomona in European dog vaccines. He suggested there was a need for studies in which serovar Mozdok, rather than serovar Pomona, was included as a test antigen because this serovar is present in a number of European rodent species to which dogs would have exposure [the striped field mouse (*Apodemus agrarius*), the great white-toothed shrew (*Crocidura russula*) and the Algerian mouse (*Mus spretus*)]. While seroprevalences to serovar Mozdok were also very low in this study, the data from the inclusion of the recently isolated serovar

Altodouro as a test antigen questions the conclusion of Ellis [14]. In our study, one in 20 dogs had evidence of exposure to this serovar and there was statistical evidence indicating that serovar Altodouro was associated with clinical disease in dogs. There would therefore be a case for the inclusion of a Pomona serogroup strain in Greek dog vaccines. Whether serovar Pomona, which is present in vaccines in the USA, may be appropriate would depend on whether such vaccines could be shown to cross-protect against serovar Altodouro.

Serovar Altodouro has only been isolated very recently – from house mice (*Mus musculus*) in northern Portugal [16]. The finding that it is a much more

sensitive antigen for the exposure of Greek dogs to Pomona serogroup infection may have important implications for what is known about these infections in other European countries and whether there is a need for the inclusion of a Pomona serogroup strain in European dog vaccines. More canine seroprevalence studies across Europe using this antigen are now required.

Seroprevalence data for the last 20 years indicates widespread exposure of dogs to serovar Bratislava infection in Europe [11, 12, 21–25]. There are a number of known maintenance hosts for this serovar – hedgehogs, pigs and horses [26, 27] and probably dogs [22]. Serovar Bratislava was the second most common serovar to which dogs were found to be exposed in this study. This is consistent with the findings of Burriel et al. [15]. They also showed that serovar Bratislava may infect a range of other domestic animals in Greece.

A case for the inclusion of serovar Grippotyphosa in dog vaccines has been made by Ellis [14] but the findings in that study would not support the need for it in Greece. This may be because the ranges of the known carrier rodent hosts [the common vole (Microtus arvalis), the root vole (Microtus oeconomus), the muskrat (Ondatra zibethicus), and the common hamster (Cricetus cricetus)] of serovar Grippotyphosa do not extend to Greece.

There was no obvious significance regarding any of the risk factors (age, sex, urban/rural origin) and exposure to any of the five Leptospira serovars included in the study. Only serovar Altodouro was found to be statistically significant when associated with one risk factor – age. The finding in the current study is that seroreactivities to Altodouro were of much higher incidence in young dogs (0–5·9 years). It suggests that the younger animals play a particularly important part in the epidemiology of infection. It confirms other published results [28, 29] which showed that younger dogs are more severely affected by leptospirosis than older dogs. However, a different situation was observed for serovars Grippotyphosa and Mozdok for which the risk of infection was greater in older (>10 years) and middle-aged (6–9·9 years) dogs, respectively. Those dogs may be more active outside their normal home environment than young dogs, increasing potential exposure to those two serovars, mainly maintained by wild-life hosts.

Regarding differences between rural and urban dogs, in spite to the observation that reactive samples were greater for rural than for urban dogs, no significant differences were found between the two populations. Moreover, no significant statistical differences in seroprevalence were found between sexes, although predisposition for leptospiral infection in males has been previously suggested [23].

This study has shown that, in northern Greece, dogs are being exposed to infection by strains of the Pomona serogroup, serovar Bratislava and occasionally serovar Grippotyphosa and that an association can be shown between infection with serovar Altodouro (Pomona serogroup) and clinical disease in dogs. Whether dogs are persistently infected by any of these can only be assessed by a renal culture study.

These findings support the view that inclusion of a Pomona serogroup strain and serovar Bratislava should be considered for dog vaccines in Greece and may indicate the need for proportional studies across Europe.

An important aspect of the study is its zoonotic implications. Since humans and dogs in part share their environment, humans are also basically exposed [2, 30]. Dogs, as a significant reservoir for human infection, were seen to be an important source of outbreaks [31]. For example, urine shedding by infected dogs played a major role in the outbreaks of human leptospirosis in Nicaragua in 1995 [32]. Dogs were also recognized as important risk factor for human leptospirosis in Barbados [33] and a potential reservoir for this disease in Germany [6].

To control leptospirosis in dogs, vaccination is essential and considered to be the front-line defence against the disease. Its purpose, besides reducing the severity of the clinical signs, is to prevent renal infection and urine shedding. This is important in order to limit the zoonotic risk and transmission of the pathogens between animal populations [7, 34–36].

DECLARATION OF INTEREST

None.

REFERENCES

1. **Adler B, de la Pena Moctezuma A.** Leptospira and leptospirosis. *Veterinary Microbiology* 2010; **140**: 287–296.
2. **Brown K, Prescott J.** Leptospirosis in the family dog: a public health perspective. *Canadian Medical Association Journal* 2008; **178**: 399–401.
3. **Andre-Fontaine G.** Canine leptospirosis – do we have a problem? *Veterinary Microbiology* 2006; **117**: 19–24.
4. **Faine S,** *et al. Leptospira and Leptospirosis*, 2nd edn. Melbourne: MediSci, 1999.
5. **Rojas P,** *et al.* Detection and quantification of leptospires in urine of dogs: a maintenance host for the zoonotic disease leptospirosis. *European Journal of Clinical Microbiology & Infectious Diseases* 2010; **29**: 1305–1309.
6. **Jansen A,** *et al.* Leptospirosis in Germany, 1962–2003. *Emerging Infectious Diseases* 2005; **11**: 1048–1054.
7. **Bisias G,** *et al.* Leptospirosis: an important re-emerging infection of animals and man. *Journal of the Hellenic Veterinary Medical Society* 2010; **61**: 76–84.
8. **Papa A, Theoharidou D, Antoniadis A.** Pulmonary involvement and leptospirosis, Greece. *Emerging Infectious Diseases* 2009; **15**: 834–835.
9. **Sion ML,** *et al.* Acute renal failure caused by leptospirosis and *Hantavirus* infection in an urban hospital. *European Journal of Internal Medicine* 2002; **13**: 264–268.
10. **Jull D J, Heath KR.** The evaluation of a combined L. canicola and L. icterohaemorrhagiae vaccine on hamsters and dogs. *Journal of Small Animal Practice* 1961; **1**: 245–258.
11. **Gerlach T, Stephan I.** Epidemiologic situation of canine leptospirosis in the Northern states of Germany in the years 2003–2006. A retrospective study. *Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere* 2007; **35**: 421–429.
12. **Geisen V, Stengel C, Hartmann K.** Epidemiologic situation of leptospirosis in dogs in the Southern states of Germany. *Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere* 2008; **36**: 329–336.
13. **Davies M.** Leptospirosis in dogs [Comment]. *Veterinary Record* 2008; **163**: 579.
14. **Ellis WA.** Control of canine leptospirosis in Europe: time for a change. *Veterinary Record* 2010; **167**: 602–605.
15. **Burriel AR, Dalley C, Woodward MJ.** Prevalence of Leptospira species among farmed and domestic animals in Greece. *Veterinary Record* 2003; **153**: 146–148.
16. **Paiva-Cardoso MN.** Epidemiological importance of rodents as reservoirs of *Leptospira* in Maronesa cattle farms in Tras-os-Montes region (Ph.D. thesis). Vila Real, Portugal: Universidade de Tras-os-Montes e Alto Duoro, 2009, pp. 272.
17. **Wolff JW.** *The Laboratory Diagnosis of Leptospirosis.* Springfield: Charles C. Thomas, 1954, pp. 99.
18. **Ellis WA, Michna SW.** Bovine leptospirosis: a serological and clinical study. *Veterinary Record* 1976; **99**: 387–391.
19. **Bland JM, Altman DG.** Statistics notes: the odds ratio. *British Medical Journal* 2000; **320**: 1468.
20. **Cabrevetanabreve N, Fodor I.** Research regarding the prevalence of leptospirosis in stray dogs. Lucrabreveri Stiintifice – Universitatea de Stiinte Agronomice si Medicinabreve Veterinarabreve Bucuresti. *Seria C Medicinabreve Veterinarabreve* 2006; **40**: 322–327.
21. **Rey F.** Prevalence of *Leptospira interrogans* infection in dogs in Switzerland. *Schweizer Archiv fur Tierheilkunde* 1987; **129**: 381.
22. **Brem S, Kopp H, Meyer P.** *Leptospira* antibody detection in dog serum in the years 1985 to 1988. *Berliner und Munchener Tierarztliche Wochenschrift* 1990; **103**: 6–8.
23. **Van den Broek AHM,** *et al.* A serological and bacteriological survey of leptospiral infection in dogs in Edinburgh and Glasgow. *Journal of Small Animal Practice* 1991; **32**: 118–124.
24. **Cerri D,** *et al.* Epidemiology of Leptospirosis: observations on serological data obtained by a 'Diagnostic laboratory for leptospirosis' from 1995 to 2001. *Microbiologica* 2003; **26**: 383–389.
25. **Scanziani E,** *et al.* Serological survey of leptospiral infection in kennelled dogs in Italy. *Journal of Small Animal Practice* 2002; **43**: 154–157.
26. **Ellis WA,** *et al.* Leptospiral infection in horses in Northern Ireland: serological and microbiological findings. *Equine Veterinary Journal* 1983; **15**: 317–320.
27. **Ellis WA,** *et al.* Prevalence of *Leptospira* infection in aborted pigs in Northern Ireland. *Veterinary Record* 1986; **118**: 63–65.
28. **Claus A,** *et al.* Leptospirosis in dogs: a retrospective study of seven clinical cases in Belgium. *Vlaams Diergeneeskundig Tijdschrift* 2008; **77**: 259–263.
29. **Hartman EG,** *et al.* Clinical, pathological and serological features of spontaneous canine leptospirosis. An evaluation of the IgM- and IgG-specific ELISA. *Veterinary Immunology and Immunopathology* 1986; **13**: 261–271.
30. **Houwers DJ,** *et al.* Agglutinating antibodies against pathogenic *Leptospira* in healthy dogs and horses indicate common exposure and regular occurrence of subclinical infections. *Veterinary Microbiology* 2011; **148**: 449–451.
31. **Levett PN.** Leptospirosis. *Clinical Microbiology Reviews* 2001; **14**: 296–326.
32. **Trevejo RT,** *et al.* Epidemic leptospirosis associated with pulmonary hemorrhage – Nicaragua, 1995. *Journal of Infectious Diseases* 1998; **178**: 1457–1463.
33. **Douglin CP,** *et al.* Risk factors for severe leptospirosis in the parish of St. Andrew, Barbados. *Emerging Infectious Disease* 1997; **3**: 78–80.
34. **Broughton ES, Scarnell J.** Prevention of renal carriage of leptospirosis in dogs by vaccination. *Veterinary Record* 1985; **12**: 307–311.
35. **Schreiber P,** *et al.* Prevention of renal infection and urinary shedding in dogs by a *Leptospira* vaccination. *Veterinary Microbiology* 2005; **108**: 113–118.
36. **Schreiber P,** *et al.* Prevention of a severe disease by a *Leptospira* vaccination with a multivalent vaccine. *Revue de Médecine Vétérinaire* 2005; **156**: 427–432.